142.26
price down icon0.97%   -1.40
pre-market  Pre-mercato:  141.49   -0.77   -0.54%
loading

Biogen Inc Borsa (BIIB) Ultime notizie

pulisher
01:27 AM

Is it time to cut losses on Biogen Inc.Portfolio Risk Report & Safe Entry Zone Tips - newser.com

01:27 AM
pulisher
12:08 PM

Key metrics from Biogen Inc.’s quarterly dataQuarterly Trade Review & Capital Efficient Trading Techniques - newser.com

12:08 PM
pulisher
Oct 16, 2025

Is Biogen Now an Opportunity After Recent 25% Share Price Decline? - simplywall.st

Oct 16, 2025
pulisher
Oct 16, 2025

Is a relief rally coming for Biogen Inc. holdersTrade Exit Summary & Verified Stock Trade Ideas - newser.com

Oct 16, 2025
pulisher
Oct 16, 2025

Alzheimer's Disease Market: Epidemiology, Therapies, - openPR.com

Oct 16, 2025
pulisher
Oct 16, 2025

Looking at the Changing Narrative for Biogen After Recent Pipeline and Market Developments - Yahoo Finance

Oct 16, 2025
pulisher
Oct 16, 2025

3 Reasons BIIB is Risky and 1 Stock to Buy Instead - The Globe and Mail

Oct 16, 2025
pulisher
Oct 15, 2025

(BIIB) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com

Oct 15, 2025
pulisher
Oct 15, 2025

When is the best time to exit Biogen Inc.July 2025 Review & Capital Protection Trading Alerts - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Is Biogen Inc. stock a safe buy before earningsJuly 2025 Drop Watch & Stepwise Trade Execution Plans - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Autoinjectors Market 2025: Industry Drug Delivery, Smart - openPR.com

Oct 15, 2025
pulisher
Oct 15, 2025

Sector ETF performance correlation with Biogen Inc.July 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Using portfolio simulators with Biogen Inc. includedInsider Selling & AI Powered Trade Plan Recommendations - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Is Biogen Inc. (IDP) stock a buy on weaknessPortfolio Update Report & Real-Time Chart Pattern Alerts - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact - GuruFocus

Oct 15, 2025
pulisher
Oct 15, 2025

Biogen (BIIB) Valuation: Assessing Market Discount After Recent Signs of Financial Stabilization - simplywall.st

Oct 15, 2025
pulisher
Oct 14, 2025

Biogen sees negative impact on Q3 EPS from IPR&D expense - Seeking Alpha

Oct 14, 2025
pulisher
Oct 14, 2025

Biogen expects $2 million research and development expense in Q3 2025 - Investing.com India

Oct 14, 2025
pulisher
Oct 14, 2025

Biogen expects estimated charge to impact net income per diluted share for Q3 by $-0.01 - MarketScreener

Oct 14, 2025
pulisher
Oct 14, 2025

CD40 Targeting Therapy Clinical Trials Anti CD40 Antibody Therapy Market Opportunity Assessment Insight - GlobeNewswire Inc.

Oct 14, 2025
pulisher
Oct 14, 2025

Wedbush Raises Price Target on Biogen to $135 From $129, Keeps Neutral Rating - MarketScreener

Oct 14, 2025
pulisher
Oct 14, 2025

LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - ACN Newswire

Oct 14, 2025
pulisher
Oct 14, 2025

Can Biogen Inc. stock double in next 5 yearsProduct Launch & Stepwise Entry/Exit Trade Alerts - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

Volatility clustering patterns for Biogen Inc.Weekly Profit Analysis & Real-Time Sentiment Analysis - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

1 Healthcare Stock to Research Further and 2 We Find Risky - FinancialContent

Oct 14, 2025
pulisher
Oct 13, 2025

Eisai and Biogen's LEQEMBI IQLIK™ Named One of TIME's "Best Inventions of 2025" for Alzheimer's Treatment - Quiver Quantitative

Oct 13, 2025
pulisher
Oct 13, 2025

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - PR Newswire

Oct 13, 2025
pulisher
Oct 13, 2025

Is Biogen Inc. stock a top momentum playTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Biogen Inc. (BIIB) Stock Analysis: Exploring a 17% Potential Upside Amidst Robust Neurological Portfolio - DirectorsTalk Interviews

Oct 13, 2025
pulisher
Oct 12, 2025

Biogen (BIIB): Revisiting Valuation After Recent Pipeline and Partnership Developments - Yahoo Finance

Oct 12, 2025
pulisher
Oct 11, 2025

Valeo Financial Advisors LLC Invests $225,000 in Biogen Inc. $BIIB - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know - The Globe and Mail

Oct 10, 2025
pulisher
Oct 10, 2025

BIIB: Morgan Stanley Raises Price Target for Biogen to $149 | BI - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? - Yahoo Finance

Oct 10, 2025
pulisher
Oct 10, 2025

Biogen and Stoke add to zorevunersen data package in Dravet syndrome - The Pharma Letter

Oct 10, 2025
pulisher
Oct 10, 2025

Biogen Inc.'s (NASDAQ:BIIB) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? - 富途牛牛

Oct 10, 2025
pulisher
Oct 10, 2025

Biogen, Stoke Therapeutics Present Positive Long-Term Data for Zorevunersen in Dravet Syndrome - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

Q3 Earnings Estimate for Biogen Issued By Leerink Partnrs - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Using data filters to optimize entry into Biogen Inc.2025 EndofYear Setup & Stock Portfolio Risk Control - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

What to Expect From Biogen’s Q3 2025 Earnings Report - MSN

Oct 10, 2025
pulisher
Oct 10, 2025

Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace

Oct 10, 2025
pulisher
Oct 09, 2025

Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome - Nasdaq

Oct 09, 2025
pulisher
Oct 09, 2025

Biogen (NASDAQ:BIIB) Earns Sell (D+) Rating from Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Biogen invests $250,000 into Durham Tech’s Life Sciences Center - CBS 17

Oct 09, 2025
pulisher
Oct 09, 2025

Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Sy - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Biogen and Stoke Therapeutics Announce Positive Long-Term Results of Zorevunersen in Dravet Syndrome at Child Neurology Society Annual Meeting - Quiver Quantitative

Oct 09, 2025
pulisher
Oct 09, 2025

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - Biogen

Oct 09, 2025
pulisher
Oct 09, 2025

Biogen & Stoke: Zorevunersen Shows 95% Clinical Improvement at 3 Years | BIIB Stock News - Stock Titan

Oct 09, 2025
pulisher
Oct 09, 2025

Where Does Biogen Stand After Recent 7% Rally Amid Alzheimer’s Drug Developments? - simplywall.st

Oct 09, 2025
pulisher
Oct 09, 2025

RBC Capital Sticks to Its Buy Rating for Biogen (BIIB) - The Globe and Mail

Oct 09, 2025
pulisher
Oct 09, 2025

Biogen's Comeback: Why The Bulls Are Finally Winning Again (NASDAQ:BIIB) - Seeking Alpha

Oct 09, 2025
pulisher
Oct 09, 2025

NC governor recognizes Biogen milestone as biotech giant celebrates recent investments in Triangle - CBS 17

Oct 09, 2025
pulisher
Oct 09, 2025

Is Biogen Inc. (IDP) stock a defensive play amid uncertainty2025 Fundamental Recap & Weekly High Return Forecasts - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Biogen Pledges $250,000 Donation to Durham Technical Community College to Mark 30th Year Anniversary in Research Triangle Park - Biogen

Oct 09, 2025
pulisher
Oct 09, 2025

Eisai and Biogen Leqembi Iqlik: The Best Inventions of 2025 - Time Magazine

Oct 09, 2025
pulisher
Oct 09, 2025

Simplicity Wealth LLC Makes New $430,000 Investment in Biogen Inc. $BIIB - MarketBeat

Oct 09, 2025
pulisher
Oct 08, 2025

Why Are Analysts Bullish on Biogen Inc. (BIIB) Now? - MSN

Oct 08, 2025
pulisher
Oct 08, 2025

Governor Stein to celebrate Biogen's 30th anniversary, spotlight biotech growth - WCTI

Oct 08, 2025
drug_manufacturers_general SNY
$50.02
price up icon 2.17%
drug_manufacturers_general PFE
$24.23
price down icon 0.66%
$117.85
price down icon 0.38%
$295.81
price down icon 0.51%
drug_manufacturers_general NVO
$56.09
price down icon 1.11%
drug_manufacturers_general MRK
$83.92
price down icon 0.23%
Capitalizzazione:     |  Volume (24 ore):